Skip to navigation Skip to content



Negative Results from Phase 2 Clinical Trial of Laquinimod in Primary Progressive MS

December 1, 2017

A phase 2 clinical trial of oral laquinimod in people with primary progressive MS did not meet its primary endpoint of slowing brain atrophy (shrinkage) after 48 weeks, and did not slow progression of disability. The results were announcement by Active Biotech, a company that has been partnering with Teva Pharmaceuticals Industries in the development of Laquinimod.
“This is disappointing news,” noted Bruce Bebo, PhD, Executive Vice President of Research at the National MS Society. “The treatment landscape is changing with the first therapy for primary progressive MS approved in 2017, but we still have a long way to go to find solutions for everyone living with MS.”
Additional details will be published and presented at a future medical conference.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.